AndhraNews.net
Home » Features » Health » Hepatitis A

Hepatitis A


About Hepatitis A

Sinovac Biotech Ltd. (Nasdaq: SVA) is a leading supplier of vaccines for Hepatitis A.

Hepatitis A in News

Harvey Alter Receives 2015 Fries Prize for Improving Health
ATLANTA, GA--(Marketwired - October 06, 2015) - Harvey Alter, M.D., M.A.C.P

Global Isothermal Nucleic Acid Amplification Technology (INAAT) (Infectious Diseases, Blood Screening, Research) Market - Forecast to 2018
Research and Markets (http://www.researchandmarkets.com/research/bwm3rb/isothermal) has announced the addition of the "Isothermal Nucleic Acid Amplification Technology (INAAT) (Infectious Diseases, Blood Screening, Research) Market - Forecast to 2018" report to their offering.

Important Kids' Health Topic
(Family Features) As a parent, you make decisions every day to keep your child safe and healthy, which include keeping your child up-to-date on vaccines to help protect against serious diseases.

P&G Delivers its 7 Billionth Liter of Clean Drinking Water in Global Effort to Save One Life Every Hour by 2020
Procter and Gamble (P&G) has announced that its non-profit Children’s Safe Drinking Water Program (CSDW) provided its 7 billionth liter of clean drinking water to a family in Brazil, as part of P&G’s Clinton Global Initiative (CGI) commitment to save one life every hour by the year 2020

Official Roster of Teams Announced in the $10 Million Qualcomm Tricorder XPRIZE
XPRIZE today announced the 34 registered teams competing for the Qualcomm Tricorder XPRIZE, a 3.5-year global competition sponsored by the Qualcomm Foundation that will award $10 million to teams that develop a consumer-friendly, mobile device capable of diagnosing and interpreting a set of 15 conditions and capturing vital health metrics

Adults: Immunizations Are Not Just for Kids
That's right. The need for immunizations doesn't end with childhood. Each year, thousands of adults in the United States suffer serious health problems, are hospitalized, or even die from diseases that could be prevented by vaccines, including influenza, whooping cough, certain bacterial infections, hepatitis A and B, shingles, and even some cancers including cervical cancer and liver cancer

U.S. EPA Approves Ocean Bio-Chem's New Liquid Disinfectant, Xtrem-A-Cide P(R) -- Effective Against Salmonella, Hepatitis A, Influenza-A, E-Coli, Numerous Other Viruses and Fungi
Ocean Bio-Chem, Inc. (NASDAQ: OBCI), a leading manufacturer and distributor of appearance, performance, and maintenance products serving the marine, automotive, power sports, recreational vehicle and outdoor power equipment markets, is pleased to announce the U.S

Guidelines Released for $10 Million Qualcomm Tricorder X PRIZE Reveal Health Condition Sets for Winning Solution
The X PRIZE Foundation announced that final competition guidelines have been released and team registration is officially open for the $10 million Qualcomm Tricorder X PRIZE, a 3.5-year global competition to stimulate innovation and integration of precision diagnostic technologies, intended to make reliable health diagnoses available directly to consumers anytime, anywhere

FDA Approves Octaplas® Expanding Octapharma U.S. Transfusion Medicine Therapies
Octapharma USA has announced that the U.S. Food and Drug Administration (FDA) has approved Octaplas®, its solvent/detergent treated pooled human plasma

Novartis receives FDA approval for Flucelvax®, the first cell-culture vaccine in US to help protect against seasonal influenza
Novartis International AG /Novartis receives FDA approval for Flucelvax®, the first cell-culture vaccine in US to help protect against seasonal influenza . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Crucell and Scripps Research Discover and Describe Broad-spectrum Antibodies against Influenza B, a Crucial Link in Development of Universal Flu Therapies and Vaccine
In a landmark discovery, researchers from Crucell Holland B.V. and The Scripps Research Institute, today announced the identification of the first human monoclonal antibodies that appear capable of disabling all influenza B viruses. The discovery, published today in the journal Science, addresses a significant missing link in development of universal therapies and a vaccine

Genital Herpes vaccine comes closer to reality
Scientists have come up with an investigational vaccine that can protect some women against infection from one of the two types of herpes simplex viruses that cause genital herpes.

Liverpool Varsity launches iphone app, HEP i-chart, for Hepatitis C treatment
UK-based University of Liverpool has launched an iphone app, HEP i-chart, which provides Hepatitis C (HCV) patients with quick and easy access to the latest information about drug interactions.

Now, engineer comes out with India's first safety intravenous cannule to prevent needle stick injuries
Forty-year-old M K Maan of Mecmaan Healthcare has come up with a safety intravenous cannule, a device that prevents needle stick injuries among healthcare workers.

Crucell Discovers Important New Antibody Against Influenza A
Leiden, The Netherlands (July 7, 2011) - Dutch biopharmaceutical company Crucell N.V. and The Scripps Research Institute today published an article in the world's leading journal of original scientific research Science describing Crucell's novel anti-influenza antibody CR8020 and how it neutralizes group 2 influenza A viruses

Mellow Hope (HTDS) Two Vaccines Approved in Pakistan
Hard to Treat Diseases, Inc. (PINK SHEETS: HTDS) (www.htdsmedical.com) announced that its China-based Shenzhen Mellow Hope subsidiary has had two vaccines for contagious diseases approved by Pakistan's Ministry of Health to be sold in the country.

Mellow Hope (HTDS) Increases Indian Vaccine Sales
Hard to Treat Diseases, Inc. (PINK SHEETS: HTDS) (www.htdsmedical.com) announced that its China-based Shenzhen Mellow Hope subsidiary had a major leap in sales volume for its Hepatitis A (MEVAC-A) vaccine in India in 2010 compared to a year earlier.

Crucell Intends to Delist Ordinary Shares on NYSE Euronext
Dutch biopharmaceutical companyCrucell N.V. (NYSE Euronext, NASDAQ: CRXL) (SWISS: CRX) today announcedthat it has obtained the approval of Euronext Amsterdam N.V. toterminate thelisting of its ordinary shares (Ordinary Shares) on NYSE Euronext inAmsterdam(NYSE Euronext).

Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs
New Brunswick, N.J., and Leiden, the Netherlands, 8 March 2011 - Johnson & Johnson (NYSE: JNJ) and Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that following the end of the subsequent offering period (na-aanmeldingstermijn, Subsequent Offering Period), Johnson & Johnson has acquired 98.89% of the issued Shares in Crucell N.V

Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional
New Brunswick, N.J., and Leiden, the Netherlands, 22 February 2011 - Johnson & Johnson (NYSE: JNJ) and Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announce that Johnson & Johnson has completed the tender offer for Crucell N.V. (Crucell) and has declared the offer unconditional

Minimum Acceptance Condition Satisfied
Johnson &Johnson (NYSE: JNJ) and Crucell N.V. (NYSE Euronext, NASDAQ: CRXL;SwissExchange: CRX) today announced that the minimum acceptance condition ofJohnson& Johnson's Offer to acquire Crucell N.V. (Crucell) has been satisfied.Theinitial offering period of the Offer expired at 17:45 hours Dutch time(11:45a.m. New York time) on 16 February 2011.

Minimum Acceptance Condition Satisfied
New Brunswick, N.J., and Leiden, the Netherlands, February 17, 2011 - Johnson & Johnson (NYSE: JNJ) and Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that the minimum acceptance condition of Johnson & Johnson's Offer to acquire Crucell N.V. (Crucell) has been satisfied

Comment on this story

Share